[Cerebrolysin treatment of mild cognitive impairment of vascular genesis].

AIM: To evaluate effects of cerebrolysin on cognitive functions in patients with mild cognitive impairment of vascular genesis. MATERIAL AND METHODS: The examination covered 43 patients aged 40 to 80 years with mild cognitive impairment. We used Tinetti scale for assessment of dynamics in postural disorders; neuropsychological examination was based on Short Scale of Psychic Status Assessment, Mattis Dementia Scale, ADAS- Cog scale, digit test and other tests. Cerebrolysin was injected in drops intravenously in a dose 10 ml per 200 ml of the physiological solution. The course included 20 injections with immediate assessment of the response and 3 months after the course. RESULTS: Cerebrolysin improved motor activity, memory, attention, general cognitive status. The effect is delayed and was noticeable 3 months after the end of the treatment course. Side effects were absent. CONCLUSION: Cerebrolysin influences neurodynamic aspects of mnestic and cognitive activity associated with frontal-subcortical relations that also results in motor activity improvement.

[The effect of cerebrolysin on moderate cognitive impairment in cerebral vascular insufficiency (a clinical and electrophysiological study)].

The efficacy of cerebrolysin has been studied in 40 patients with cerebral vascular insufficiency and moderate cognitive impairment. The treatment in dosage of 10 ml cerebrolysin per 200 ml of physiological solution (20 intravenous injections daily) was effective in this group of patients. The course therapy with cerebrolysin reduced memory and attention disturbances improving the total cognitive status of patients. The data of clinical observations and neuropsychological testing have been confirmed by the results of electrophysiological study (cognitive event-related potential P300). The therapeutic effect had a delayed character being observed 3 month after completion of the treatment course.

[Cognitive potential P300 in dementia with Levy's bodies and Alzheimer's disease].

Neurodegenerative diseases accompanied by cognitive impairment (dementia with Levy's bodies--DLB and Alzheimer's disease--AD) and others) are becoming more widespread due to increasing population life expectancy. The paper addresses use of cognitive event-related potential P300 to verbal and nonverbal stimuli with an assessment of interhemispheric asymmetry and topographic distribution of P300 in patients with DLB and AD comparied to age-matched healthy controls. Specific alterations of P300 amplitude and latency suggest a use of cognitive event-related potential P300 in differential diagnosis of DLB and AD.

[Cognitive potential p300 in Parkinson disease]. / Kognitivnyi potentsial p300 pri bolezni Parkinsona.

Cognitive evoked potential P300 in response to visual verbal and non-verbal stimuli was examined in 40 patients with idiopathic Parkinson's disease (PD) without cognitive impairment and 8 age- and sex matched normal controls. All the patients were subjected to clinical and neuropsychological evaluation. The influence of patient's age, duration, type and severity of the disease, debut's lateralization and anti-parkinsonic therapy efficacy on P300 was evaluated. Compared to controls, PD patients exhibited a significantly prolonged P300 latency and decreased P300 peak amplitude. The topography of PD maximum P300 amplitude indicated a frontal distribution with no between-hemispheres differences. Overall, the P300 changes in PD patients without dementia can be interpreted as a decrease of directed activity level and the partial defect of mental recognition processes and stimuli differentiation related mostly to the nonverbal image-spatial cognitive processes. The results show that P300 recording may be useful for diagnosis of subclinical cognitive disturbances in PD without dementia.